AFTER DOUBLING MONEY IN THIS FAMOUS BIOTECH RELATED TO APPLE, WHAT IS NEXT? $AAAP $AAPL $NEOS $NVS $PDLI $GILD $JUNO $ZIOP $BLCM $BLUE

Not long ago, French pharmaceutical company Advanced Accelerator Applications got a lot of publicity. Now it’s getting bought out. The late Apple AAPL, co-founder Steve Jobs died from pancreatic cancer, specifically from a neuroendocrine tumor, or ...
Read more »

INTELLIGENCE: CONGRATULATIONS TO THOSE WHO BOUGHT BIOTECH FIRM KITE PHARMA, $180 BUYOUT OFFER $KITE $GILD

This post was just published on ZYX Buy Change Alert.   KITE is a biotech firm focused on cancer using engineered T-cell therapy.  When The Arora Report had provided intelligence on KITE it was trading around $54.27.  Now GILD ...
Read more »

You are receiving less than 2% of the content from our paid services ...TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES.

Please click here to take advantage of a FREE 30 day trial.

Check out our enviable performance in both bull and bear markets.

TRUMP’S ‘OBAMACARE LITE’ PRESENTS OPPORTUNITIES AND PERILS FOR INVESTORS $XBI $MDT $BSX $EW $CYH $THC $PFE $JNJ $MRK $BMY $TEVA $MYL

Republicans have finally produced a detailed plan to repeal and replace the Affordable Care Act, also known as Obamacare. Setting aside politics and viewing the plan neutrally, two things jump out. First, the House Republicans’ plan ...
Read more »

OBAMACARE IS DEAD, WELCOME TRUMPCARE OPPORTUNITIES! $SPY $XLV $XHS $PJP $XBI $IHI $BMY $JNJ $PFE $MRK $ABT $ABBV $LLY $HUM $UNH $AET $ANTH $CI $HCE $CVH $THC $CNC $MOH

Democrats will fight tooth and nail to save Obamacare, but given the flaws in the plan, they are not likely to succeed. Obamacare in its current form is the walking dead. Trump has said that he ...
Read more »

You are receiving less than 2% of the content from our paid services ...TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES.

Please click here to take advantage of a FREE 30 day trial.

Check out our enviable performance in both bull and bear markets.

INTELLIGENCE: CAR-T CANCER IMMUNOTHERAPY PROMISING BUYOUT TARGETS AFTER ASTRAZENECA $AZN $CLLS $JUNO $BLCM $XON $ZIOP $KITE $BLUE $ADXS $LBIO

This post was just published on ZYX Buy Change Alert. For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria ...
Read more »
Follow

Get every new post delivered to your Inbox

Join other followers